ETH 154
Alternative Names: ETH-154Latest Information Update: 25 Aug 2023
Price :
$50 *
At a glance
- Originator Shengke Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase modulators; TrkC receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Adenoid cystic carcinoma; Squamous cell cancer
Most Recent Events
- 25 Aug 2023 ETH 154 is available for licensing as of 25 Aug 2023. https://www.shengketx.com/pipeline/
- 24 Jul 2023 Early research in Adenoid cystic carcinoma in China (unspecified route) (Shengke Pharmaceuticals pipeline, July 2023)
- 24 Jul 2023 Early research in Squamous cell cancer in China (unspecified route) (Shengke Pharmaceuticals pipeline, July 2023)